{"url_path":"/sec/emma/8-k/2026-05-15/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operation and Financial","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/822370/0001213900-26-057828-index.html","accession_number":"0001213900-26-057828","cik":"0000822370","ticker":"EMMA","issuer_name":"Emmaus Life Sciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/822370/0001213900-26-057828-index.html","primary_entity_key":"0000822370","primary_entity_name":"Emmaus Life Sciences, Inc."},"word_count":136,"has_tables":true,"body_markdown":"**Item 2.02 Results of Operation and Financial\nCondition.**\n\n \n\nOn May15, 2026, Emmaus Life\nSciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) issued a press\nrelease announcing our results of operations and financial condition as of and for the three months ended March 31, 2026, a copy of which\nis included as Exhibit 99.1 to this Current Report and incorporated herein by reference.\n\n \n\nThe\ninformation included in this Item 2.02 and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities\nExchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed\nincorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific\nreference in such a filing."}